(Q40404169)

20 September 2017

Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy (English)

1 reference

20 September 2017

0 references

Rui Li

1

0 references

Simon Fillatreau

object named as

Simon Fillatreau

13

0 references

Jennifer L Gommerman

object named as

Jennifer L Gommerman

11

0 references

Amit Bar-or

14

object named as

Amit Bar-Or

1 reference

20 September 2017

12

Alexandre Prat

1 reference

20 September 2017

Craig S Moore

7

0 references

author name string

Ayman Rezk

2

1 reference

20 September 2017

Yusei Miyazaki

3

1 reference

20 September 2017

Ellen Hilgenberg

4

1 reference

20 September 2017

Hanane Touil

5

1 reference

20 September 2017

Ping Shen

6

1 reference

20 September 2017

Laure Michel

8

1 reference

20 September 2017

Faisal Althekair

9

1 reference

20 September 2017

Sathy Rajasekharan

10

1 reference

20 September 2017

Canadian B cells in MS Team

15

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 October 2015

1 reference

Science Translational Medicine

20 September 2017

1 reference

20 September 2017

7

1 reference

20 September 2017

310

1 reference

20 September 2017

310ra166

1 reference

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

20 September 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

B-cell depleting agents for ANCA vasculitides: a new therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Regulatory roles for cytokine-producing B cells in infection and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Immune regulatory function of B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Autoimmunity: regulatory B cells--IL-35 and IL-21 regulate the regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Innate response activator B cells protect against microbial sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

B cells regulate autoimmunity by provision of IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Interleukin-35 induces regulatory B cells that suppress autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAB4176

10.1126/SCITRANSLMED.AAB4176

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference